viernes, 13 de noviembre de 2009

Conjunctivitis.


GUIDELINE TITLE
Conjunctivitis.

BIBLIOGRAPHIC SOURCE(S)
American Academy of Ophthalmology Cornea/External Disease Panel, Preferred Practice Patterns Committee. Conjunctivitis. San Francisco (CA): American Academy of Ophthalmology (AAO); 2008. 30 p. [110 references]


GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: American Academy of Ophthalmology Cornea/External Disease Panel, Preferred Practice Patterns Committee. Conjunctivitis. San Francisco (CA): American Academy of Ophthalmology (AAO); 2003. 25 p.

All Preferred Practice Patterns are reviewed by their parent panel annually or earlier if developments warrant and updated accordingly. To ensure that all Preferred Practice Patterns are current, each is valid for 5 years from the "approved by" date unless superseded by a revision.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT

Note from the National Guideline Clearinghouse: This guideline references drugs for which important revised regulatory information has been released.

August 14, 2009 - CellCept (mycophenolate mofetil), September 04, 2009 - Myfortic (mycophenolic acid): The U.S. Food and Drug Administration (FDA) and Roche notified healthcare professionals that cases of Pure Red Cell Aplasia (PRCA) have been reported in patients treated with CellCept. Additionally, the USDA and Novartis notified healthcare professionals that cases of PRCA have been reported in patients treated with Myfortic. The WARNINGS and ADVERSE REACTIONS sections of the Prescribing Information for both drugs have been revised to reflect this new safety information.
July 14, 2009 - Sirolimus (Rapamune), Cyclosporine (Sandimmune or Neoral and generics), Mycophenolate mofetil (Cellcept and generics), Mycophenolic acid (Myfortic): The U.S. Food and Drug Administration (FDA) is requiring the makers of certain immunosuppressant drugs to update their labeling to reflect that immunosuppressed patients are at increased risk for opportunistic infections, such as activation of latent viral infections, including BK virus-associated nephropathy.
February 12, 2009 and March 24, 2009 update - CellCept (mycophenolate mofetil) and Myfortic (mycophenolic acid): The U.S. Food and Drug Administration (FDA) and Roche Laboratories notified healthcare professionals of the introduction of a CellCept Medication Guide to provide important safety information in language that patients can easily comprehend and regulations that require a pharmacist to distribute a copy of the Medication Guide to every patient who fills a CellCept prescription. FDA and Novartis notified healthcare professionals of the introduction of a Myfortic Medication Guide that will be enclosed with every Myfortic bottle as of May 15, 2009.

abrir aquí para acceder al documento NGC AHRQ completo:
Conjunctivitis.

No hay comentarios:

Publicar un comentario